Fig. 3From: Impact of high dose of baricitinib in severe COVID-19 pneumonia: a prospective cohort study in Bangladesh60-day rehospitalization rate of patients with severe COVID-19 infection treated with high (case) or usual (control) oral dose of baricitinib for 14 daysBack to article page